MD3830120T2 - Noi proteine de fuziune specifice pentru CD137 și PD-L1 - Google Patents

Noi proteine de fuziune specifice pentru CD137 și PD-L1

Info

Publication number
MD3830120T2
MD3830120T2 MDE20210513T MDE20210513T MD3830120T2 MD 3830120 T2 MD3830120 T2 MD 3830120T2 MD E20210513 T MDE20210513 T MD E20210513T MD E20210513 T MDE20210513 T MD E20210513T MD 3830120 T2 MD3830120 T2 MD 3830120T2
Authority
MD
Moldova
Prior art keywords
fusion protein
fusion proteins
fusion
nucleic acid
protein specific
Prior art date
Application number
MDE20210513T
Other languages
English (en)
Inventor
Marina Pavlidou
Lucia Pattarini
Alix Scholer-Dahirel
Christine Rothe
Shane Olwill
Aiba Rachida Bel
Marlon Hinner
Janet Peper
Original Assignee
Pieris Pharmaceuticals Gmbh
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pieris Pharmaceuticals Gmbh, Servier Lab filed Critical Pieris Pharmaceuticals Gmbh
Publication of MD3830120T2 publication Critical patent/MD3830120T2/ro
Publication of MD3830120T3 publication Critical patent/MD3830120T3/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Dezvăluirea se referă la protein de fuziune specific atât pentru CD137 cât şi pentru PD-L1, care protein de fuziune pot fi utilizate să co-stimuleze activarea limfocitelor într-o manieră dependent de PD-L1-ţintă. Astfel de proteine de fuziune pot fi utilizate оn multe aplicaţii farmaceutice, de exemplu ca agenţi anti-cancer şi/sau ca modulatori imuni pentru tratamentul sau prevenţia bolilor umane, cum ar fi diferite tumori. Dezvăluirea de faţă se referă totodată la metode de fabricare a proteinelor de fuziune descries aici precum şi compoziţii care cuprind astfel de protein de fuziune. Dezvăluirea de faţă se referă în continuare la molecule de acizi nucleic care codifică astfel de protein de fuziune şi la metode pentru genearea de astfel de protein de fuziune şi molecule de acizi nucleic. În plus, cererea dezvăluie utilizăti terapeutice şi/sau de diagnostic al acestor protein de fuziune precum şi ale compoziţiilor care conţin una sau mai multe astfel de protein de fuziune.
MDE20210513T 2018-07-31 2019-07-31 Noi proteine de fuziune specifice pentru CD137 și PD-L1 MD3830120T3 (ro)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18186445 2018-07-31
EP18204548 2018-11-06
PCT/EP2019/070596 WO2020025659A1 (en) 2018-07-31 2019-07-31 Novel fusion protein specific for cd137 and pd-l1

Publications (2)

Publication Number Publication Date
MD3830120T2 true MD3830120T2 (ro) 2023-08-31
MD3830120T3 MD3830120T3 (ro) 2023-11-30

Family

ID=67480227

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20210513T MD3830120T3 (ro) 2018-07-31 2019-07-31 Noi proteine de fuziune specifice pentru CD137 și PD-L1

Country Status (26)

Country Link
US (1) US20210363257A1 (ro)
EP (2) EP3830120B9 (ro)
JP (1) JP7482488B2 (ro)
KR (1) KR20210040103A (ro)
CN (1) CN112789292A (ro)
AU (1) AU2019315703A1 (ro)
BR (1) BR112020025263A2 (ro)
CA (1) CA3100119A1 (ro)
CL (1) CL2021000207A1 (ro)
CY (1) CY1126148T1 (ro)
DK (1) DK3830120T3 (ro)
ES (1) ES2948717T3 (ro)
FI (1) FI3830120T3 (ro)
HR (1) HRP20230590T2 (ro)
HU (1) HUE062320T2 (ro)
IL (1) IL279541A (ro)
LT (1) LT3830120T (ro)
MD (1) MD3830120T3 (ro)
MX (1) MX2021000401A (ro)
PH (1) PH12021550001A1 (ro)
PL (1) PL3830120T3 (ro)
RS (1) RS64343B9 (ro)
SG (1) SG11202100989UA (ro)
SI (1) SI3830120T1 (ro)
WO (1) WO2020025659A1 (ro)
ZA (1) ZA202100125B (ro)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3121288A1 (en) * 2018-11-29 2020-06-04 Harbour Biomed Therapeutics Limited Anti-pd-l1 antibody preparation
EP4041772A4 (en) 2019-10-11 2024-04-24 Nanjing Leads Biolabs Co Ltd 4-1BB-BINDING ANTIBODIES AND USES THEREOF
EP4161957A1 (en) 2020-06-05 2023-04-12 Pieris Pharmaceuticals GmbH Multimeric immunomodulator targeting 4-1bb
CN116710556A (zh) * 2021-01-08 2023-09-05 北京韩美药品有限公司 抗pd-l1/抗4-1bb天然抗体结构样异源二聚体形式双特异抗体及其制备
CN115521379B (zh) * 2021-07-16 2023-12-22 南京吉盛澳玛生物医药有限公司 Pd-1抗体及其用途
CN114736303A (zh) * 2022-03-17 2022-07-12 英诺湖医药(杭州)有限公司 抗pd-l1和4-1bb的双功能抗体及其医药用途
WO2023180523A1 (en) 2022-03-24 2023-09-28 Pieris Pharmaceuticals Gmbh Process for purifying fusion proteins
WO2024064713A1 (en) * 2022-09-21 2024-03-28 Seagen Inc. Novel fusion protein specific for cd137 and cd228
CN116211860B (zh) * 2023-05-10 2023-08-22 细胞生态海河实验室 Ck2抑制剂cx4945在制备肿瘤治疗中防止免疫细胞耗竭药物应用、抑制剂及联合物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
CA2334267C (en) 1998-06-08 2009-02-17 F. Hoffmann-La Roche Ag Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
EP1377306A1 (en) 2001-03-09 2004-01-07 Dyax Corp. Serum albumin binding moieties
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
JP2009509535A (ja) 2005-09-27 2009-03-12 アムニクス， インコーポレイテッド タンパク様薬剤およびその使用
WO2015104406A2 (en) * 2014-01-13 2015-07-16 Pieris Ag Multi-specific polypeptide useful for localized tumor immunomodulation
CA2980839A1 (en) * 2015-05-04 2016-11-10 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
CA2980838A1 (en) * 2015-05-18 2016-11-24 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
SG10201912405TA (en) * 2016-01-11 2020-02-27 Inhibrx Inc Multivalent and multispecific 41bb-binding fusion proteins
JP6432121B2 (ja) * 2016-03-04 2018-12-05 シチュアン ケルン−バイオテック バイオファーマシューティカル カンパニー リミテッド Ｐｄｌ−１抗体、その医薬組成物及びその使用
KR101996019B1 (ko) * 2016-06-13 2019-07-03 아이-맵 항-pd-l1 항체 및 이것의 사용
WO2018087108A1 (en) * 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
JP7145895B2 (ja) * 2017-09-01 2022-10-03 四川科倫博泰生物医薬股▲フン▼有限公司 組換え二重特異性抗体
WO2023000675A1 (zh) * 2021-07-23 2023-01-26 安徽安科生物工程（集团）股份有限公司 靶向pd-l1和4-1bb的双特异性抗体

Also Published As

Publication number Publication date
LT3830120T (lt) 2023-07-10
CN112789292A (zh) 2021-05-11
WO2020025659A1 (en) 2020-02-06
HUE062320T2 (hu) 2023-10-28
CL2021000207A1 (es) 2021-08-13
HRP20230590T1 (hr) 2023-09-15
BR112020025263A2 (pt) 2021-03-09
PL3830120T3 (pl) 2023-10-09
IL279541A (en) 2021-01-31
EP3830120B9 (en) 2023-08-30
RS64343B1 (sr) 2023-08-31
KR20210040103A (ko) 2021-04-12
DK3830120T3 (da) 2023-06-26
CA3100119A1 (en) 2020-02-06
SI3830120T1 (sl) 2023-10-30
EP4249064A3 (en) 2023-12-06
JP7482488B2 (ja) 2024-05-14
EP3830120B1 (en) 2023-05-24
ES2948717T3 (es) 2023-09-18
PH12021550001A1 (en) 2021-09-27
EP4249064A2 (en) 2023-09-27
TW202019967A (zh) 2020-06-01
EP3830120A1 (en) 2021-06-09
ZA202100125B (en) 2023-06-28
AU2019315703A1 (en) 2020-12-10
US20210363257A1 (en) 2021-11-25
JP2021533203A (ja) 2021-12-02
HRP20230590T2 (hr) 2024-02-16
CY1126148T1 (el) 2023-11-15
FI3830120T3 (fi) 2023-06-13
RS64343B9 (sr) 2023-11-30
SG11202100989UA (en) 2021-02-25
MX2021000401A (es) 2021-03-25
MD3830120T3 (ro) 2023-11-30

Similar Documents

Publication Publication Date Title
MD3830120T3 (ro) Noi proteine de fuziune specifice pentru CD137 și PD-L1
MX2021010039A (es) Novedosas proteinas de fusion especificas para cd137 y gpc3.
EA202090817A1 (ru) Триспецифические белки и способы их применения
MD3880654T2 (ro) Compuși 2-formil-3-hidroxifeniloximetilici capabili de modularea hemoglobinei
CL2017002767A1 (es) Nuevas proteínas específicas para cd137.
MX2020011257A (es) Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
MD3303379T2 (ro) Agenți de legare TIGIT și utilizări ale acestora
AU2016277883A8 (en) PD-1-CD28 fusion proteins and their use in medicine
MA33930B1 (fr) Nouveaux anticorps antagonistes contre gpvi et leurs fragments fab et utilisations de ceux-ci
EA201991207A1 (ru) Новые агонисты tnfr и их применение
ATE409181T1 (de) Proteomimetische verbindungen und verfahren
BR112019000692A8 (pt) Moduladores de somatostatina e usos destes
EA200801570A1 (ru) Стабильные белковые препараты
EA201791841A1 (ru) Новые белки, специфичные к пиовердину и пиохелину
EA201992570A1 (ru) Составы на основе человеческих антител к rankl, а также способы их применения
BR112021019070A2 (pt) Ligantes de pseudoquinase tyk2
FR3034993B1 (fr) Conditionnement unitaire, compositions et schemas therapeutiques pour l'administration de stimulateurs des voies de pro-resolution sur des surfaces keratiniques
EA202290054A1 (ru) Полиспецифические антитела, содержащие только тяжелые цепи, которые связываются с cd22 и cd3
MX2022002315A (es) Anticuerpos anti-cd96 y sus metodos de uso.
BR112021015616A2 (pt) Ligantes de pseudoquinase tyk2
TR201910117T4 (tr) OspA nın mutant fragmanları ve bunlara ilişkin yöntemler ve kullanımları.
PH12020551955A1 (en) Anti-cd63 antibodies, conjugates, and uses thereof
BR112022000855A2 (pt) Moduladores de nlrp3
BR112021014566A2 (pt) Moduladores de gpr35
EA202193040A1 (ru) Конъюгат анти-всма антитела, композиции, содержащие данный конъюгат, и способы его получения и применения

Legal Events

Date Code Title Description
TH4A Change/correction in patent specification

Free format text: CHANGE/CORRECTION IN INID